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Abstract
Mutations in glucocerebrosidase (GBA) are the most prevalent genetic risk factor for Lewy body disorders (LBD)—collec-
tively Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies. Despite this genetic association, 
it remains unclear how GBA mutations increase susceptibility to develop LBD. We investigated relationships between LBD-
specific glucocerebrosidase deficits, GBA-related pathways, and α-synuclein levels in brain tissue from LBD and controls, 
with and without GBA mutations. We show that LBD is characterised by altered sphingolipid metabolism with prominent 
elevation of ceramide species, regardless of GBA mutations. Since extracellular vesicles (EV) could be involved in LBD 
pathogenesis by spreading disease-linked lipids and proteins, we investigated EV derived from post-mortem cerebrospinal 
fluid (CSF) and brain tissue from GBA mutation carriers and non-carriers. EV purified from LBD CSF and frontal cortex 
were heavily loaded with ceramides and neurodegeneration-linked proteins including alpha-synuclein and tau. Our in vitro 
studies demonstrate that LBD EV constitute a “pathological package” capable of inducing aggregation of wild-type alpha-
synuclein, mediated through a combination of alpha-synuclein–ceramide interaction and the presence of pathological forms 
of alpha-synuclein. Together, our findings indicate that abnormalities in ceramide metabolism are a feature of LBD, con-
stituting a promising source of biomarkers, and that GBA mutations likely accelerate the pathological process occurring in 
sporadic LBD through endolysosomal deficiency.
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Lewy body disorders (LBD) encompass Parkinson’s 
disease (PD), Parkinson’s disease dementia (PDD) and 
dementia with Lewy bodies (DLB), a spectrum of dis-
orders pathologically characterised by neuronal alpha-
synuclein aggregation [1]. The end stages of PDD and 
DLB are clinically and neuropathologically similar sug-
gesting that analogous pathological processes exist [43]. 
Glucocerebrosidase (GBA) gene mutations are the most 
prevalent genetic risk factors for LBD [65, 82], and 
reduced glucocerebrosidase (GBA) activity is also appar-
ent in sporadic LBD [17, 64], suggesting a common defect 
in lysosomal metabolism.
GBA (EC 3.2.1.45) is a lysosomal hydrolase involved 
in complex glycosphingolipid catabolism, converting 
glucosylceramide and glucosylsphingosine into glucose 
and ceramide or sphingosine, respectively. Severe defi-
ciency of GBA activity due to homozygous or compound 
heterozygous mutation of GBA is the cause of Gaucher’s 
disease [40]. However, accumulating evidence demon-
strates that heterozygous mutation of GBA and subsequent 
reduced GBA enzymatic activity is not sufficient by itself 
to induce neuronal alpha-synuclein pathology, since there 
is a significant overlap of GBA activities between GBA 
mutation carriers and healthy controls [50]. These obser-
vations indicate that both the loss of normal function as 
well as a gain of toxic function by mutant GBA protein 
might contribute to the risk of alpha-synuclein accumula-
tion in LBD. Although there is no evidence of significant 
accumulation of GBA substrates in the brains of GBA 
mutation carriers [18, 32], elevated glucosylceramide 
leads to the formation of high-molecular weight alpha-
synuclein species [59]. Reduced GBA activity does not 
induce alpha-synuclein aggregation; however, it enhances 
pre-existing alpha-synuclein pathology [38]. The underly-
ing mechanism behind the effects of GBA in LBD remains 
largely unclear; however, it potentially involves lysosomal 
dysfunction due to (age-related) alpha-synuclein accu-
mulation and loss of cellular homeostasis due to GBA 
haploinsufficiency.
It is plausible that in GBA heterozygotes, lipids directly 
related to abnormal GBA activity are released from neu-
rons by the exosomal transport system in a similar man-
ner to the enhanced exosomal secretion of cholesterol in 
Niemann–Pick disease type C [84], which appears to be 
a protective mechanism to eliminate lipid accumulation 
in cells. Exosomes are formed via the action of endoso-
mal sorting complexes required for transport (ESCRT) 
machinery or ceramide-dependent mechanisms within 
the endolysosomal pathway [88]. It is likely that changes 
in the endolysosomal system affect cargo sorting, the 
production of vesicles and their contents, and subsequently 
the inter-cellular signalling. Endoplasmic reticulum stress 
can induce the release of extracellular vesicles (EV) con-
taining damage-associated molecular pattern (DAMP) 
molecules with a suggested role in systemic inflamma-
tion [19, 44]. This is mediated through the stress related 
activation of autophagy [67] in an attempt to reduce pro-
tein-related stress through the increase of secretion. Endo-
plasmic reticulum stress and lysosomal abnormalities are 
present in LBD and GBA mutation carriers [31, 50] and we 
hypothesised that EV contents might be changed in these 
pathologies and involved in disease pathogenesis.
The aims of the current study were to (1) provide a global 
lipidomic and proteomic analysis of EV from sporadic LBD 
and GBA-associated LBD post-mortem cerebrospinal fluid 
(CSF) and frontal cortex tissue; (2) provide brain lipid pro-
files from large cohorts of LBD and GBA-associated LBD 
compared to controls and elderly neuropathologically intact 
GBA controls; and (3) characterise alpha-synuclein in EV 
for potential aggregation-promoting properties. We demon-
strate that changes in sphingolipid levels are present in LBD 
brain and EV, but that GBA carriers do not show greater 
sphingolipid changes. Our study also shows that neurode-
generation-linked proteins are present in LBD EV and these 
EV induce alpha-synuclein aggregation. These novel data 
add to the body of evidence that GBA modulates the risk of 
alpha-synucleinopathies, rather than induces it, and EV are 
involved in disease propagation.
Materials and methods
Brain tissue
Fifty-nine samples of post-mortem frontal cortex and 48 
samples of cingulate cortex from matched LBD, LBD with 
heterozygous GBA mutations, controls with and without het-
erozygous GBA mutations were provided by the Newcastle 
Brain Tissue Resource. Additional samples (n = 2) of frontal 
cortex and cingulate cortex were derived from the Manches-
ter Brain Bank (MRC ID BBN_3206 and BBN_3395) with 3 
samples of frontal cortex obtained from the Edinburgh Brain 
and Tissue Bank (BBN_2551, BBN_2367 and BBN_2576). 
Post-mortem cerebrospinal fluid (CSF) samples (n = 15) 
were received from the Newcastle Brain Tissue Resource 
(Online Resource Table  1 and 2). All procedures were 
approved by the National Health Service Research Ethics 
Committee and appropriate informed consent was obtained 
from donors or next of kin for tissue donation.
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Purification of extracellular vesicles 
from post‑mortem CSF
Frozen post-mortem CSF samples were thawed on ice and 
vortexed vigorously. CSF was pre-cleared by centrifugation: 
1500×g, then 3000×g and 10,000×g for 10 min each at 4 °C. 
If more than 500 μl of CSF was available, the sample was con-
centrated using VivaSpin 2 centrifugal concentrators Molecu-
lar Weight Cut Off (MWCO) 3 kDa (Sartorius) to 500 μl. CSF 
samples, 500 µl, were then loaded onto size exclusion chro-
matography (SEC) columns (qEV original, Izon). Fractions 
were eluted with Phosphate Buffered Saline (PBS, Sigma), 
according to the manufacturer’s instructions. EV were con-
tained within fractions 7, 8 and 9, 500 µl each, and those were 
collected to one tube and concentrated (VivaSpin 2 Sartorius 
MWCO 3 kDa) to 500 μl. Isolated EV were aliquoted to avoid 
freeze thaws and stored at − 80 °C. An aliquot of each sample 
was analysed for particle concentration and size by Tunable 
Resistive Pulse Sensing (TRPS, Izon). TRPS provides accurate 
measurements since it analyses individual particles as they 
translocate through a single nanopore compared to estimates 
provided by light scattering-based methods [90].
Frozen frontal cortex extracellular vesicle 
purification
EV were purified from frozen frontal cortex according to an 
extensively modified protocol [68]. A minimum of 600 mg 
of frozen frontal cortex was thawed on ice and finely minced 
using a pair of scalpels. Tissue was then dissociated in Hiber-
nate E (Gibco, ThermoFisher) supplemented with 5 mM 
L-cysteine (Sigma) and papain (Sigma, final concentration 20 
units/ml) at 37 °C for 15 min with shaking. Hibernate E with 
protease inhibitor cocktail (Roche) was added to a total vol-
ume of 10 ml and tissue was gently homogenised by passing 
through a 10 ml serological pipette. Dissociated tissue was 
filtered using a 40 μm mesh filter (Fisher Scientific) and the 
filtrate centrifuged at 300×g for 10 min, 2000×g for 10 min 
and then 10,000×g for 30 min to remove cell debris and larger 
microvesicles. With each step, the supernatant was collected, 
and the final supernatant was filtered again using a 0.45 μm 
filter (VWR) and concentrated to 500 μl (VivaSpin Turbo 4 
MWCO 3 kDa, Sartorius). This sample was applied to a SEC 
column (qEV original) and processed for EV isolation as pre-
viously outlined for CSF EV. Representative samples were 




Brain tissue and EV lipids were extracted in methanol/chlo-
roform (2/1, v/v) containing internal standards representa-
tive of major lipid classes (Online Resource Table 3). The 
mixture was then left to stand at 4 °C for 1 h after which 
it was centrifuged (750×g for 5 min) to remove precipi-
tated proteins. The extract was evaporated to dryness under 
nitrogen gas and reconstituted in methanol containing 5 mM 
ammonium formate (1 ml for brain and 150 µl for EV).
Mass spectrometry of lipids
Lipidomic analyses were performed using a Thermo 
Exactive Orbitrap mass spectrometer equipped with a heated 
electrospray ionisation probe and coupled to a Thermo 
Accela 1250 UHPLC system. Brain and EV lipids were ana-
lysed in both positive and negative ion mode over the mass 
to charge (m/z) range 250–2000 at a resolution of 100,000. 
Samples were injected onto a Thermo Hypersil Gold C18 
column (1.9 µm; 2.1 mm × 100 mm) maintained at 50 °C. 
The mobile phase A consisted of water containing 10 mM 
ammonium formate and 0.1% (v/v) formic acid. The mobile 
phase B consisted of 90:10 isopropanol/acetonitrile contain-
ing 10 mM ammonium formate and 0.1% (v/v) formic acid. 
The initial conditions for analysis were 65%A/35%B. The 
percentage of mobile phase B was increased from 35 to 65% 
over 4 min, followed by 65%–100% over 15 min, with a hold 
for 2 min before re-equilibration to the starting conditions 
over 6 min. The flow rate was 400 μl/min. For the targeted 
separation of glucosyl- and galactosylceramides in brain 
and EV lipid extracts, an Advanced Materials Technology 
HALO HILIC column (2.7 µm; 4.6 mm × 150 mm) was used 
according to the method of Boutin et al. 2016 [12].
Lipidomics data processing
The raw LC–MS data were processed with Progenesis QI 
software (version 2.1, Nonlinear Dynamics). Lipid iden-
tifications were made by searching against LIPID MAPS 
(www. lipid maps. org/) and HMDB (http:// www. hmdb. ca/).
Statistical analysis of differences in levels of quantified 
lipids in all groups of cases was performed by one-way 





Protein extraction, quantification, reduction, and alkylation
EV samples were lysed in either 8 M Urea, 5 mM Triethyl-
ammonium Bicarbonate (TEAB) pH 8.5 (in solution) or 5% 
SDS, 50 mM TEAB pH 7.55 (S-Trap), sonicated and protein 
quantification was determined using the BCA Protein Assay 
Kit (Pierce Protein). Each sample was reduced by adding 
TCEP to a final concentration of 10 mM for 30 min at room 
temperature followed by alkylation with 10 mM iodoaceta-
mide for 30 min in the dark.
S‑Trap protein digestion
Samples were acidified by addition of 2.5 µl of 12% phos-
phoric acid and diluted with 165 µl of S-Trap binding buffer: 
90% MeOH, 100 mM TEAB, pH 7.1. The acidified samples 
were then loaded onto an S-Trap spin column and centri-
fuged for 1 min at 4000×g. Columns were washed five times 
with S-Trap binding buffer before addition of porcine trypsin 
(1:20; Pierce) in 25 µl of 50 mM TEAB to the column. Sam-
ples were incubated at 47 °C for 2 h. Peptides were eluted 
by washing the column first with 50 mM TEAB, pH 8.0 (40 
µl), followed by 0.2% formic acid (FA; 40 µl) and finally 
0.2% FA, 50% acetonitrile (ACN; 40 µl). Peptides were then 
dried under vacuum before being resuspended in 0.1% TFA 
prior to injection.
Mass spectrometry
Label‑free mass spectrometry acquisition
Peptide samples were separated on an Ultimate 3000 RSLC 
system (Thermo Scientific) with a C18 PepMap, serving as 
a trapping column (2 cm × 100 µm ID, PepMap C18, 5 µm 
particles, 100 Å pore size) followed by a 50 cm EASY-Spray 
column (50 cm × 75 µm ID, PepMap C18, 2 µm particles, 
100 Å pore size) (Thermo Scientific). Buffer A contained 
0.1% FA and Buffer B 80% ACN, 0.1% FA. Peptides were 
separated with a linear gradient of 1–35% (Buffer B) over 
120 min followed by a step from 35 to 90% ACN, 0.1% FA 
in 0.5 min at 300 nl/min and held at 90% for 4 min. The gra-
dient was then decreased to 1% Buffer B in 0.5 min at 300 nl/
min for 10 min. Mass spectrometric identification was per-
formed on an Orbitrap QE HF mass spectrometer (Thermo 
Scientific) operated in “Top Speed” data dependant mode 
in positive ion mode. FullScan spectra were acquired in a 
range from 400 m/z to 1500 m/z, at a resolution of 120,000 
(at 200 m/z), with an automated gain control (AGC) of 
1,000,000 and a maximum injection time of 50 ms. Charge 
state screening was enabled to exclude precursors with a 
charge state of 1. For MS/MS fragmentation, the minimum 
AGC was set to 5000 and the most intense precursor ions 
were isolated with a quadrupole mass filter width of 1.6 m/z 
and 0.5 m/z offset. Precursors were subjected to collision 
induced dissociation (CID) fragmentation that was per-
formed in one-step collision energy of 25%. MS/MS frag-
ments ions were analysed in the Orbitrap mass analyser with 
a 15,000 resolution at 200 m/z.
Mass spectrometry data analysis
Protein identification and label-free quantification was per-
formed using MaxQuant Version 1.6.10.43. Trypsin/P set 
as enzyme; stable modification carbamidomethyl (C); vari-
able modifications Oxidation (M), Acetyl (Protein N-term), 
Deamidation (NQ), Gln and Glu to pyro-Glu; maximum 6 
modifications per peptide, and 2 missed cleavages. Searches 
were conducted using the Uniprot human database (March 
28, 2021) including common contaminants. Identifications 
were filtered at a 1% FDR at the peptide level, accepting a 
minimum peptide length of 5. Quantification was performed 
using razor and unique peptides and required a minimum 
count of 2. “Match between runs” was enabled. LFQ intensi-
ties were extracted for each protein/condition and used for 
downstream analyses. For hierarchical clustering, the inten-
sities were first transformed to Z-score and subjected to t test 
in Perseus 1.6.2.1. Hits with p < 0.05 were then clustered 
by Euclidean distance in R using ‘pheatmap’ package and 
the enrichment of Gene Ontology terms in each cluster was 
determined by the DAVID web-based tool (https:// david. 
ncifc rf. gov/).
Expression and purification of alpha‑synuclein
Human alpha-synuclein was expressed from plasmid 
pRK172 (a kind gift of Goedert) [41]. E. coli BL21(λ DE3) 
STAR cells (Novagen) were transformed with the pRK172 
plasmid and grown at 37 °C in medium containing 100 µg/
ml ampicillin to an OD600 ≈ 0.6 and then grown for an 
additional 30 min at 20 °C. Expression was induced by 
1 mM IPTG. Cells were harvested 15–18 h after induction, 
resuspended in buffer A (25 mM Tris/HCl buffer, pH 7.7 
complemented with Complete EDTA-free protease inhibitor 
(Roche)) at a 4:1 buffer/pellet ratio and lysed by four passes 
through an Emulsiflex (Avestin). The lysate was centrifuged 
for 30 min at 12,000×g at 4 °C. Purification followed a pub-
lished protocol [45], briefly the supernatant was passed 
through a 0.22 µm filter (Merck) before being loaded onto a 
HiTrap Q HP column (GE Healthcare) on an Äkta Pure sys-
tem (GE Healthcare). Alpha-synuclein was applied in buffer 
A to the column and eluted with a linear gradient to buffer 
A complemented with 500 mM NaCl. Alpha-synuclein con-
taining fractions were concentrated to 2–3 ml using 10 kDa 
MWCO centrifugal filters (Merck). To avoid the presence of 
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large molecular alpha-synuclein species, the protein solution 
was filtered through a 100 kDa MWCO centrifugal filter 
(Merck). The concentrated alpha-synuclein was applied to 
a Superdex75 column (GE Healthcare) equilibrated with 
PBS buffer. Fractions containing alpha-synuclein were then 
collected, pooled and flash frozen in liquid nitrogen before 
storage at -80 °C.
Isotope labelling
We obtained [U-15N,13C]-labelled alpha-synuclein by grow-
ing the expression cells in M9 minimal media [76], supple-
mented with (15NH4)Cl and D-(13C)-glucose. All isotopes 
were purchased from Sigma-Aldrich.
NMR spectroscopy
NMR measurements were performed on a Bruker AvanceIII 
800 MHz spectrometer running Topspin 3.5, equipped with 
a cryogenically cooled TXO triple-resonance probe. All 
NMR experiments were performed in NMR buffer (PBS, 
pH 7.4) and at a temperature of 281 K. The sequence-spe-
cific backbone resonance assignment of alpha-synuclein 
was taken from a previous study [16]. For titration experi-
ments 2D  [15N,1H]-SOFAST-HMQC [79] experiments were 
recorded with inter-scan delays of 200 ms and 1024 × 128 
complex points as well as CON-IPAP spectra were acquired 
with 1024 complex points for the 13CO dimension and 128 
increments for the 15N-dimension [resulting from 256 IPAP 
(in-phase/antiphase) increments] [8, 9].
For quantitative analysis of signal intensities, the ampli-
tudes were corrected by differences in the 1H-90° pulse 
length, the number of scans, and the dilution factor [92]. 
Further, a weighting function with weights 1-2-1 for residues 
(i − 1) − i − (i + 1) was applied to the raw data [15, 63]. 
NMR data were processed TopSpin 4.0 (Bruker BioSpin), 
NMRpipe [22], and mddnmr [42] as well as subsequently 
analysed with CARA [46]. The chemical shift changes of 
the amide moiety were calculated as follows:
Real‑time quaking‑induced conversion (RTQuIC) 
assay
Protein aggregation assay was performed as described pre-
viously [23]. Fifteen μl of purified EV were subjected to 
RTQuIC against positive (alpha-synuclein pre-formed fibrils 
1:1000 dilution of 1 mg/ml stock) and negative controls 
(unseeded reaction). Increase in Thioflavin T fluorescence 
was measured every 15 min (Ex/Em 450/480 nm) using a 











Brain tissue homogenate preparation 
and fractionation
Samples of frozen cingulate cortex tissue were thawed 
and dissected on ice and homogenised in 5 volumes (w/v) 
of 0.2 M Triethylammonium bicarbonate buffer (TEAB, 
Sigma) supplemented with 5 mM EDTA (Sigma) and pro-
tease inhibitors cocktail (Roche) using a Precellys Evolution 
homogeniser. Homogenates were centrifuged at 25,830×g 
for 1 h at 4 °C and supernatants were labelled as TEAB-
soluble fractions. Pellets were washed with the homogenisa-
tion buffer and resuspended in homogenisation buffer with 
addition of 1% Triton-X100 (final concentration, Sigma). 
Samples were then vortexed extensively, incubated on 
ice for 20–30 min and spun at 25,830×g for 1 h at 4 °C. 
Supernatant samples were labelled as Triton-X100-soluble 
fractions. Pellets were re-extracted in the same buffer and 
spun as before. Supernatants were stored but not used in the 
following assays and pellets were washed and resuspended 
in 2.5 volumes (of the original amount of homogenisation 
buffer) of TEAB buffer containing 8% SDS/8 M Urea. Sam-
ples were spun at 25,830×g for 1 h at 22 °C. Supernatants 
were labelled as SDS/Urea-soluble fractions. A Pierce BCA 
assay kit (ThermoFisher) was used to determine protein con-
centration of all fractions.
Western blot
Eighteen µl of EV extracts or 15–20 μg of total brain tis-
sue protein were subjected to Sodium Dodecyl Sulphate-
Polyacrylamide Gel Electrophoresis (SDS-PAGE; NuPAGE 
4–12% Bis–Tris gel, Invitrogen) according to the manufac-
turer’s instructions. Tetraspanins CD63 and CD81 were 
analysed under non-reducing conditions. Samples were 
heated (70 °C, 10 min) before loading onto the gel, except 
for SDS/Urea brain tissue fractions which were not heated. 
SDS-PAGE gels were transferred to Polyvinylidene Fluoride 
(PVDF) membranes (iblot 2, Invitrogen). Membranes were 
incubated with primary antibodies overnight at 4 °C, fol-
lowed by washes with 1 × Tris Buffered Saline (TBS, Santa 
Cruz Biotechnology)-0.1% Tween (TBST) and incubation 
with appropriate HRP-conjugated secondary antibodies 
(Dako, Agilent) for an hour at room temperature. Primary 
antibodies were: GBA (Sigma, 1:1000), GAPDH (Santa 
Cruz Biotechnology, 1:2000), Alix (Cell Signalling, 1:500), 
SNAP25 (Sigma, 1:2000), CD63 (Abcam, 1:500), CD81 
(Abcam, 1:250), Calnexin (Abcam, 1:10,000), alpha-synu-
clein (Abcam, 1:5000; BD Biosciences, 1:500 (SDS/Urea 
fraction), 1:250 (vesicular)), VDAC1/Porin (Abcam, 1:800), 
Synaptophysin (Abcam, 1:20,000) and TFAM (Abcam, 
1:2000). Signal was developed using Pierce ECL Plus West-
ern blotting substrate or SuperSignal West Femto Maximum 
Sensitivity Substrate (ThermoFisher) and detected with an 
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Amersham Imager 600 (GE Healthcare). Bands intensities 
were analysed using ImageQuant software (GE Healthcare).
Alpha‑synuclein ELISA
EV samples in PBS were thawed, supplemented with Com-
plete mini protease inhibitor cocktail tablets (Roche) and 
lysed with Triton-X100 (1% final concentration) on ice. The 
protein concentration was determined using a micro BCA 
protein assay kit (Pierce, ThermoFisher). Fifty μl of the 
lysates in duplicate were tested using a total alpha-synuclein 
ELISA. The ELISA plate was coated with anti-alpha-synu-
clein specific 10D2 antibody (amino acids 118–127 of alpha-
synuclein, Analitik Jena, 1:2000) in a coating buffer (0.2 M 
carbonate-bicarbonate buffer, pH 9.6) in a total volume of 
100 µl per well overnight at 4 °C. Wells were washed 3 
times with PBS + 0.2% Tween (PBST) and the plate blocked 
with 1% BSA in PBST on a rocking plate for 1 h. Follow-
ing a single wash with PBST, recombinant alpha-synuclein 
standards (Sigma-Aldrich; 0.001–40 ng/µl) or samples were 
prepared in PBS + 0.2% Tween, loaded in a volume of 100 µl 
per well and agitated on a rocking plate for 2 h. Wells were 
washed three times with PBST. Detection antibody against 
α/β synuclein (Abcam, 1:1500) in 1% BSA in PBST was 
added and agitated on rocking plate for 1 h, followed by 
three washes with PBST. Goat anti-rabbit AP-conjugate 
(Santa Cruz, 1:1000) in 1% BSA in PBST was incubated on 
a rocking plate for 1 h, followed by three washes in PBST. 
pNPP (p-nitrophenyl phosphate; Sigma-Aldrich) substrate 
was added (1 mg/ml in 0.05 M sodium carbonate/0.001 M 
 MgCl2), and the plate incubated at 37 °C for 30 min and 
absorbance recorded at 412 nm. Alpha-synuclein levels were 
calculated based on comparison to the standard curve and 
normalised using the total protein concentration.
Negative staining and transmission electron 
microscopy
Five μl of EV suspension in PBS was applied to glow dis-
charged carbon-coated copper grids for 1–2 min. The grids 
were wicked dry by touching with a filter paper and stained 
with 2% uranyl acetate. Grids were dried and examined 
using a Philips CM 100 Compustage (FEI) Transmission 
Electron Microscope and digital images were collected using 
an AMT CCD camera (Deben). Alpha-synuclein fibrils were 
stained according to the same protocol and examined on a 
Hitachi HT7800 transmission electron microscope using an 
Emsis Xarosa camera with Radius software.
Immuno‑electron microscopy
EV preparations were adsorbed for 30 or 60  min to 
pioloform-coated EM support grids at ice temperature. 
Adsorbed vesicles were contrasted for electron micros-
copy in films of methyl cellulose containing uranyl acetate 
or uranyl acetate/sodium silicotungstate as detailed [5]. 
All procedures were performed at ice temperature unless 
otherwise stated.
For surface antibody labelling, grids were washed twice 
in PBS before incubation with 0.5% fish skin gelatine in 
PBS (FSG; 5 min) followed by antibody diluted in FSG 
(60 min). After washes in PBS, grids were incubated with 
rabbit anti-mouse diluted 1:250 or 1:500 in FSG (30 min; 
Southern Biotech), washed in PBS and then incubated with 
10 nm protein A gold (30 min; BBI, Cardiff, UK). After 
washes in PBS and distilled water, grids were contrasted 
as detailed above. For labelling of permeabilised EV, the 
adsorbed EV were fixed in 16% paraformaldehyde in water 
for 10 min followed by washes in PBS and 0.1 M glycine 
in PBS (10 min). The EV were then permeabilised in 0.1% 
Triton X100 (5 min) and transferred to FSG gelatine and 
processed as described above. EV were imaged in a JEOL 
1200EX electron microscope equipped with a GATAN 
Orius 200 digital camera. EV were selected for quantifi-
cation using unbiased counting rule applied to a scanning 
band [36] and calliper diameters measured either directly 
on screen or estimated using stereological techniques as 
previously described [33, 36].
GBA enzyme activity assay
GBA activity assay was performed as described previously 
[50, 86] with minor modifications. Twenty μl of fraction-
ated brain tissue was used and 100 μl of GBA substrate 
(4-MUG, 4-methylumbelliferyl-β-D-glucopyranoside, 
Sigma) prepared at 5 mM final concentration in assay 
buffer (50 mM phosphate citrate buffer, pH 5.0, 0.5% 
sodium taurocholate, both Sigma). The reactions were 
carried out in 96-well black polystyrene plates (Nunc) for 
2 h at 37 °C. Control reactions with a specific GBA inhibi-
tor, conduritol beta epoxide (CBE, Sigma), were carried 
out in parallel. Tissue homogenates were pre-incubated 
with 4 mM CBE (2 mM final concentration) for 15 min at 
37 °C (inhibitor controls), following which the substrate 
was added. Reactions were stopped with 180 μl of 1 M 
glycine pH 10.5. Standards of 4-methylumbelliferone 
(4-MU; 300–0 nM) in 1 M glycine buffer were used to 
generate a reference curve. Fluorescence was measured at 
excitation 356 nm and emission 445 nm (ThermoFisher 
Varioskan Lux). GBA activity was expressed as nM of 
4-MU produced per mg of total protein and corrected by 
the amount of CBE resistant activity. Data were analysed 
for normality and parametric or non-parametric tests were 
used as appropriate to determine statistical significance, 




LBD GBA mutation carriers do not show more 
extensive alpha‑synuclein pathology compared 
to sporadic LBD
Post-mortem brain tissue (frontal and cingulate cortex) 
from clinically and neuropathologically confirmed PD, 
PDD and DLB patients (LBD) as well as age-matched 
clinically and neuropathologically confirmed controls was 
utilised in this study (Online Resource Table 1). The pres-
ence of GBA mutations (L444P, IVS2 + 1, RecNciI, L105R, 
N370S, E326K, T369M, E388K and R262H) in 14 DLB, 
3 PDD, 4 PD, and 10 controls (Online Resource Table 1 
and Online Resource Table 2) was identified using whole 
exome sequencing and validated by Sanger sequencing and/
or restriction fragment length polymorphism [47, 50]. All 
PD, PDD and DLB GBA mutation carriers presented clini-
cal and neuropathological features typical for the disorders 
as diagnosed according to McKeith’s criteria for DLB [60], 
MDS criteria for PD [71] and neuropathological staging 
according to Kosaka for DLB [49], and Braak for PD [13]. 
Alzheimer’s disease (AD) Braak neurofibrillary tangle 
stage was for DLB: range 0–4, PD: 0–2, PDD: 2–4, mode 
(for LBD) = 3. Control GBA mutation carriers were free of 
extensive age associated neuropathological changes and 
presented neuropathology typical for older individuals (AD 
Braak neurofibrillary tangle stage range 0–3, mode = 0). AD 
Braak neurofibrillary tangle stage for Lewy body disorders 
GBA non-carriers was: range 0–6, mode = 1 and control non-
carriers was: range 0–3, mode = 0. The average age at death 
for GBA mutation carriers was 75.3 ± 7.6 (LBD n = 22) and 
74.1 ± 18.5 (controls n = 10), and for GBA mutation non-
carriers was 72.2 ± 10.8 (LBD n = 17) and 74.6 ± 10.5 (con-
trols n = 16) (Online Resource Table 1).
To determine any direct relationship between alpha-
synuclein protein aggregation levels and corresponding 
levels of GBA protein and enzyme activity, cingulate cor-
tex samples from LBD and controls with and without GBA 
mutations were fractionated using the following solubilisa-
tion agents: TEAB, Triton X100 and SDS/Urea, to isolate 
soluble, membrane-bound and aggregated protein fractions, 
respectively. GBA protein levels and enzyme activities were 
statistically significantly decreased in LBD GBA mutation 
carriers (Online Resource Fig. 1) and only slightly reduced 
in control GBA mutation carriers (soluble and membrane-
bound fractions). There were no differences in GBA protein 
levels or enzyme activities in either soluble or membrane-
associated fractions between LBD and controls without GBA 
mutations (Online Resource Fig. 1). These data indicate that 
the presence of heterozygous GBA mutation leads to a reduc-
tion of GBA protein and activity levels in brain tissue.
Further comparative analysis revealed no significant 
changes in abundance of alpha-synuclein in cytoplasmic and 
membrane-bound protein fractions between GBA mutation 
carriers and non-carriers, LBD cases, and controls (Fig. 1). 
In contrast, there was an accumulation of monomeric alpha-
synuclein and alpha-synuclein high-molecular weight spe-
cies (aggregates) in SDS/Urea fractions in LBD patients with 
and without GBA mutations compared to controls. There was 
no significant difference, however, in alpha-synuclein aggre-
gate levels between LBD with GBA mutations compared to 
LBD without GBA mutations (Fig. 1). Controls with GBA 
mutations did not show any extensive alpha-synuclein aggre-
gates, which confirmed the neuropathological observations 
of an absence of any major alpha-synuclein pathology in 
controls. Overall, we observed an increase in alpha-synu-
clein aggregate accumulation in LBD patients, however this 
was independent of GBA mutation status.
Ceramides are increased in the LBD brain
Lipid accumulation within lysosomes is the major defect 
associated with GBA deficiency that causes Gaucher’s dis-
ease [14]. We, therefore, investigated potential lipid changes 
in relation to the overall alpha-synuclein burden (high in 
the cingulate versus relatively low in the frontal cortex) in 
LBD patients and age-matched controls. We performed a 
global lipidomic analysis of matched samples of post-mor-
tem frontal and cingulate cortex from clinically and neu-
ropathologically validated LBD patients and controls with 
and without GBA mutations. Hexosylceramide separation 
into glucosyl- and galactosylceramide species was per-
formed on a subset of 12 LBD and 8 control cingulate cor-
tex samples. The analysis revealed substantial differences 
in various lipid classes between LBD patients and controls 
(Fig. 2a). Notably, the most prominent changes character-
istic for LBD were in the frontal cortex tissue, in contrast 
to subtle changes in the cingulate cortex. These included 
predominantly increased levels of ceramides and decreased 
levels of diglycerides (Fig. 2a). No changes were observed 
in glucosyl- and galactosylceramide species between the dif-
ferent groups, indicating that GBA enzymatic dysfunction 
is not a prerequisite for specific ceramide accumulation in 
LBD (Fig. 2b and Online Resource Fig. 2 and 3). We did, 
however, identify statistically significant increases in lev-
els of certain ceramide species that were validated in LBD 
cases compared to controls using a quantitative approach, 
and these changes were more prevalent in the frontal cortex 
than the cingulate cortex (Fig. 2c). Interestingly, there were 
no changes characteristic of GBA mutation carriers in either 
brain region. Overall, the global lipid analysis revealed an 
elevation of ceramide levels in LBD patients compared to 





CSF extracellular vesicles are enriched in ceramides
We hypothesised that protein and lipid dysmetabolism in 
the LBD brain may influence the composition of EV that 
are known to have a role in inter-cellular communication 
and pathological alpha-synuclein distribution. We, therefore, 
purified EV from post-mortem CSF to high purity from 5 
LBD (3 DLB, 1 PDD, 1 PD) cases with GBA mutations, 6 
LBD cases (2 DLB, 2 PDD, 2 PD) without GBA mutations, 
and 4 controls without mutations in GBA (cases matching 
the brain tissue analysis). Purification of EV was performed 
by means of size exclusion chromatography, which preserves 
the morphological and functional properties of EV [11]. The 
yield and quality of CSF EV were determined using several 
methods; TRPS analysis performed on all samples deter-
mined the concentration and size of the particles (average 
mode for all samples 122.6 nm ± 9.9), transmission electron 
microscopy was used to image the particles and western blot 
and immuno-electron microscopy were employed to confirm 
the presence of known extracellular vesicles/exosome mark-
ers such as CD63, flotillin 1, Alix and Tsg101 (Fig. 3a–d). 
Global lipidomic analysis was performed on all EV samples. 
We detected statistically significant elevations in ceramide 
species in LBD compared to control vesicles, similar to 
the observations in brain tissue, with no other statistically 
significantly changed lipids identified and no lipids with 
lower levels in LBD compared to controls. Ceramides were 
quantified by comparison to internal standards included in 
the experimental system, showing a several fold increase 
in ceramide abundance in LBD EV compared to controls 
(Fig. 3e, Online Resource Fig. 5). No major effect of GBA 
mutation was seen on ceramide levels, with elevations of 
ceramide species being a general feature of LBD (Fig. 3f, 
Online Resource Fig. 4 and 6).
Alpha‑synuclein and other 
neurodegeneration‑linked proteins are present 
in LBD extracellular vesicles
EV were purified from frontal cortex tissue from 13 GBA 
mutation carriers [7 LBD (5 DLB, 2 PDD) and 6 controls] 
and 12 GBA mutation non-carriers [6 LBD (3 DLB, 2 PDD, 
1 PD) and 6 controls] [68] (Fig. 4a). EV were analysed for 
size and concentration by TRPS and imaged using transmis-
sion EM (Fig. 4b, c). The purity of EV fractions was vali-
dated based on the enrichment of exosomal markers includ-
ing CD63 and CD81, while intracellular proteins such as 
calnexin and VDAC1/porin were absent in EV fractions, 
indicating the relatively high purity of the EV isolated from 
human brain using our approach (Fig. 4d, e). Next, we vali-
dated the presence of alpha-synuclein in all frontal cortex 
EV samples using western blotting (Fig. 4e), immuno-elec-
tron microscopy (Online Resource Fig. 7), and ELISA, with 
no differences in total alpha-synuclein levels seen between 
cases and controls (Online Resource Fig. 8).
To obtain further insights into the molecular differences 
of disease-specific EV proteomes, we performed an explora-
tory label-free proteomic analysis of a subset of frontal cor-
tex EV from DLB patients and healthy controls, with and 
without GBA mutations. This resulted in the identification 
of 1586 proteins (< 1% FDR) (Online Resource Table 4). 
Gene Ontology (GO) enrichment analysis of the frontal cor-
tex EV proteomes confirmed the high purity of the samples 
(Fig. 5a). Interestingly, the proteomic analysis revealed the 
presence of neurodegeneration-linked proteins including 
alpha-synuclein, beta-synuclein, gamma-synuclein and tau 
protein in DLB and control EV, but with no statistically sig-
nificant changes in levels (Fig. 5b, Online Resource Table 4). 
The presence of GBA mutations did not have a major effect 
on the EV proteome in the small sample set screened.
To identify disease-specific proteins contained within 
DLB frontal cortex EV, proteins with significantly altered 
levels were analysed by hierarchical clustering (Fig. 5c). 
Gene Ontology Biological Process term enrichment analy-
sis for each differentially expressed protein cluster revealed 
apparent downregulation of GABAergic synaptic activity 
(Cluster 1; GABRA1, GABRA2, GABRD, GRIA3) and 
upregulation of pro-inflammatory glycolytic metabolism 
(Cluster2; HK1, ALDOA, PGK1, PGM1) in DLB EV 
(Fig. 5c, d).
Additionally, we confirmed the presence of alpha-synu-
clein in LBD and control post-mortem CSF-derived EV (sur-
face bound and internal) using immuno-electron microscopy. 
We detected alpha-synuclein in both patient and control 
samples (9 LBD and 4 control samples screened), in asso-
ciation with vesicles typically 40–200 nm diameter (Fig. 6).
Alpha‑synuclein interacts with LBD EV 
and aggregates upon exposure
As LBD EV are filled with potentially neurotoxic lipid spe-
cies and neurodegeneration-linked proteins, we thought to 
explore the interaction of wild-type alpha-synuclein with 
LBD EV. We used solution NMR spectroscopy, a technique 
used previously to interrogate alpha-synuclein–biological 
Fig. 1  Alpha-synuclein solubility in the cingulate cortex from Lewy 
body disease and controls with and without GBA mutations. Using 
soluble (cytoplasmic, TEAB), detergent-soluble (membrane bound, 
Triton X100) and insoluble (aggregates, SDS/Urea) protein fractions 
from Parkinson’s disease/Dementia with Lewy body cases and con-
trols with and without GBA mutations, we determined alpha-synu-
clein levels by western blotting. We identified the presence of high-
molecular weight alpha-synuclein species only in insoluble fractions 
from Parkinson’s disease/Dementia with Lewy body cases with an 
absence in controls, but with no difference between mutation carriers 
(MT) and wild-type GBA Lewy body disorders cases (WT). Graphs 






membrane binding at the atomic level [27]. Addition of 
equal amounts of EV samples from control and LBD fron-
tal cortex to monomeric alpha-synuclein (Online Resource 
Fig. 9a), resulted in only marginal signal intensity losses 
without any observable chemical shift changes (e.g. reso-
nance peak shifting) in the  [15N,1H]-NMR spectra reporting 
on the backbone amide moiety, the standard type of experi-
ment for studying interactions of proteins (Online Resource 
Fig.  9b–f). Nevertheless, exploiting the more sensitive 
 [15N,13C]-NMR spectra [39] indicated transient interactions 
with disease-related EV compared to the control EV (Online 
Resource Fig. 9 g–k). For the different disease-related EV, an 
interaction within the carboxy-terminus of alpha-synuclein 
centred around aromatic/hydrophobic residues was observed 
(PDD GBA WT: F94, L113, Y125; PDD GBA MT: I112; 
DLB GBA WT: L113). The observation of effects within 
the carboxy-terminus of alpha-synuclein might indicate 
no direct vesicle interaction since this interaction occurs 
via the amino-terminus [57]; however, vesicle interaction 
of the carboxy-terminus of alpha-synuclein modulated by 
 Ca2+ binding to this region enhancing its hydrophobicity 
has been reported [27, 52].
To test the effect on fibrillisation of patient-derived 
EV, we repeated the NMR interaction study with alpha-
synuclein incubated with EV for 48 h (Fig. 7a). Under 
these conditions, we could not identify any effect in 
the absence or presence of control EV (Fig.  7b, c), 
whereas disease-related EV showed distinct effects 
(Fig. 7d–h). PDD-derived EV showed clear indications 
for alpha-synuclein–vesicle binding, namely signal attenu-
ation of the amino-terminal ~ 100 amino acids similar to 
the effect observed for polar brain lipids [16, 87]. Further-
more, additional signals could be observed in proximity 
to the carboxy-terminal residues, which is a clear indica-
tion of proteolytic cleavage, which was most pronounced 
for the PDD GBA MT-derived vesicles. Overall, in both 
samples, a significant loss of signal intensity could be 
observed, indicating the presence of an NMR-indiscerni-
ble large molecular alpha-synuclein species, presumably 
fibrils. These aggregation-inducing effects of vesicles were 
particularly strong for the DLB sample analysed, which 
showed only very few and weak resonances (Fig.  7f). 
Using the three distinct species, unperturbed monomer, 
membrane-bound monomer indicated by the characteristic 
vesicle binding pattern, and the absence of NMR signal 
upon fibrillisation, as a proxy we estimated the contribu-
tions of these three species for the different samples tested 
(Fig. 7i).
The observation of the distinctive cleavage patterns in 
the different PDD EV prompted us to identify proteases 
within EV (Online Resource Fig. 10). Notably, several 
different cellular proteases previously implicated in 
alpha-synuclein processing were identified that have the 
potential to modulate alpha-synuclein aggregation [6, 10]. 
For example, the PDD GBA mutant sample that showed 
a large degree of proteolytic cleavage in the NMR spec-
trum, demonstrated upregulation of a subset of proteases 
including matrix metalloprotease ADAM22, caspase 14, 
and cathepsin D that can generate a C-terminal cleaved 
alpha-synuclein with enhanced fibrillisation propensity 
[10, 91]. The DLB GBA wild-type EV sample did not show 
the characteristic cleavage pattern on NMR; however, the 
proteomic analysis showed an upregulation of proteases 
mainly involved in cellular maintenance, such as subunits 
of the ubiquitin–proteasome system, several mitochondrial 
proteases (e.g. calpain 1), and oxidative stress response/
alpha-synuclein chaperone activity (PARK7/DJ1) [7, 94] 
(Online Resource Fig. 10).
To further validate the alpha-synuclein aggregation-
inducing effect of EV, we performed real-time quaking-
induced conversion (RTQuIC) assay using post-mortem 
CSF extracellular vesicles. Induction of aggregation of 
recombinant alpha-synuclein was observed in LBD sam-
ples, with no aggregation in controls; however, a posi-
tive signal of aggregate formation was seen in clinically 
normal controls with minimal alpha-synuclein pathology 
present (incidental Lewy bodies, Fig. 8a), indicating EV 
alpha-synuclein is highly fibrillogenic. TEM analysis of 
post-RTQuIC samples revealed abundant alpha-synuclein 
Fig. 2  Changes in lipids between LBD cases and controls identified 
using global lipidomic profiling indicate altered ceramide species. a 
Initial global lipidomic profiling identified species of lipids signifi-
cantly altered in LBD compared to controls within post-mortem fron-
tal or cingulate cortex. The majority of changes were identified in 
the frontal cortex tissue. Heatmap represents maximum fold changes 
LBD vs control frontal cortex at p < 0.005 based on relative values 
from C18 column and positive ion mode. b No change in glucosylcer-
amide or galactosylceramide concentrations was observed in the cin-
gulate cortex in LBD- or control-GBA mutation carriers and non-car-
riers. Data for specific lipid species are presented in Online Resource 
Figs. 2 and 3. c Specifically focusing on ceramides, statistically sig-
nificant elevations of ceramide species were identified in the frontal 
and cingulate cortex in the LBD group overall compared to controls 
with and without GBA mutations, with no major effect of GBA muta-
tion. Ceramides have been annotated based on the combined number 
of carbons and double bonds of the sphingoid base and N-linked fatty 
acid. A putative assignment of the fatty acyl composition is also listed 
in parentheses. Mean ± SEM shown. Statistical analysis by one-way 
ANOVA followed by post hoc Dunn’s multiple comparisons test. 
MT GBA mutation, WT wild-type GBA, no mutation present, TOTAL 
combined groups of cases, Pos positive ion mode, Neg negative ion 
mode, Cer ceramide. The majority of changes were detected in both 






fibrils and on many occasions EV trapped in the fibril net, 
suggestive of the EV contribution to alpha-synuclein fibril 
generation (Fig. 8b and Online Resource Fig. 11). Over-
all, our findings strongly indicate that alpha-synuclein 
interacts with EV and aggregates upon exposure to alpha-
synucleinopathy bearing EV.
Discussion
The association between GBA mutations and an increased 
risk of developing PD and DLB is well established [65, 82], 
but the underlying mechanism by which GBA has its effect is 
still unknown. There are several potential factors that could 
be needed to elevate the risk of alpha-synucleinopathy, as 
most individuals with heterozygous GBA mutations do not 
develop LBD, with the estimated risk of developing par-
kinsonism at 80 years being 9.1% [4]. In the current study, 
we investigated the effects of heterozygous GBA mutations 
on the brain lipidome in LBD as we hypothesised that GBA 
mutations may be associated with the loss of homeostasis 
in lipid metabolism. We extended our hypothesis to brain 
secreted EV, as pathological changes in neural cells may lead 
to an altered composition of the EV lipidome and proteome 
and consequently impact disease signalling and spread to 
other cells.
Our study clearly indicates the specific accumulation of 
ceramide species in LBD signifying abnormal sphingolipid 
metabolism. This observation corroborates other reports of 
changes in sphingolipid composition of LBD post-mortem 
tissues [18, 21], though decreased ceramide levels have 
also been reported [2, 64, 93]. Variables such as different 
anatomical regions, age, mutational profiles, disease dura-
tion and/or neuropathological staging might be relevant 
in understanding these discrepancies [25]. Our lipidomic 
analysis demonstrates an elevation of ceramides irrespective 
of GBA mutation status, indicating elevated ceramides are 
a marker of LBD. Although ceramide levels are similar in 
post-mortem GBA mutation carriers and non-carriers, the 
rate of ceramide accumulation may be accelerated in GBA 
mutation carriers, and this is suggested in plasma and serum 
studies in LBD. Notably, increased levels of ceramides have 
been found in plasma of PD cases without GBA mutation 
[61], and PD GBA mutation carriers demonstrated elevated 
ceramides in serum compared to non-carriers [35]. No sig-
nificant changes in CSF levels of ceramides were found 
between PD GBA mutation carriers and non-carriers; how-
ever, carriers of severe GBA mutations tended to have higher 
CSF ceramide, indicating the biochemical link between GBA 
mutations and elevated disease risk [53].
Our targeted lipidomic approach specifically analysing 
the levels of hexosylceramides and in particular glucosyl-
ceramides that are a substrate for GBA, indicates no change 
in overall levels compared to controls. This latter finding 
indicates that, despite mutation of GBA leading to signifi-
cantly reduced enzyme activity, there is sufficient enzyme 
activity remaining in heterozygous mutation carriers to 
effectively metabolise glucosylceramides. These findings 
correspond with previous animal and cell work demonstrat-
ing that heterozygous mutation leads to only mild changes 
and retained ability to handle cellular glucosylceramide 
species [77]. Our results indicate that loss of GBA enzyme 
activity is unlikely to be responsible for the elevated cera-
mides observed in LBD. Therefore, we hypothesise that the 
elevated ceramide levels present in LBD may come from a 
non-lysosomal fraction.
Since EV mediate transfer of alpha-synuclein species 
between cells, we investigated the lipid composition of EV. 
Global lipidomic analysis of CSF EV revealed that LBD EV 
are laden with ceramide species and show markedly elevated 
ceramide levels when compared to control EV, indicating 
that the presence of elevated ceramide species is an indi-
cator of an LBD related process. While the global lipid-
omic approach to ceramide species in bulk tissue samples 
showed modest but significant changes, the elevations of 
ceramides in CSF EV suggest that EV may provide a more 
specific indicator of ceramide dysmetabolism with changes 
in ceramide levels associated with EV production pathways. 
If ceramide dysmetabolism is an indication of underlying 
pathological processes associated with LBD (such as alpha-
synuclein aggregation), then reductions of specific ceramide 
Fig. 3  CSF extracellular vesicles are enriched in ceramides. a EV 
were purified from post-mortem CSF using size exclusion chroma-
tography, then negatively stained and visualised using transmission 
electron microscopy demonstrating typical morphology. b EV were 
analysed for particle count and size by means of tunable resistive 
pulse sensing (TRPS) and showed a typical size of between 100 and 
200 nm, with c western blotting demonstrating expression of known 
exosomal markers, and d CD63 immuno-labelling by immuno-
electron microscopy. e Significantly elevated lipids, and particularly 
ceramides, were found in CSF extracellular vesicles from LBD com-
pared to controls. LC–MS using C18 column in negative ion mode. 
Mean ± SEM shown. Statistical analysis using Mann–Whitney or 
unpaired t test with Welch’s correction. **p < 0.01, ***p < 0.001. f 
No apparent effect of GBA mutation was found on the levels of cera-
mides in LBD EV, with elevation of ceramides representing a feature 
of all LBD, not restricted to GBA mutation carriers. Representative 
data shown from C18 column and negative ion mode. Ceramides 
have been annotated based on the combined number of carbons and 
double bonds of the sphingoid base and N-linked fatty acid. A puta-
tive assignment of the fatty acyl composition is listed in parentheses. 




Fig. 4  Purification of extracel-
lular vesicles from post-mortem 
frontal cortex. a Frozen brain 
tissue was processed according 
to the scheme and b puri-
fied EV analysed for size and 
concentration using tunable 
resistive pulse sensing (TRPS) 
and c transmission electron 
microscopy. d The presence 
of known exosomal markers 
(CD63 and CD81) was veri-
fied by western blotting. e An 
absence of calnexin, VDAC1/
Porin and TFAM indicates 
the purity of EV fractions and 
lack of contamination with 
intracellular material including 
mitochondria. Certain neuronal 
vesicle-associated proteins (syn-
aptophysin and SNAP25) were 
detected in some EV prepara-
tions, although these proteins 
are also found in CSF EV [58]. 
Alpha-synuclein was present in 




levels in CSF EV may provide an indicator of therapeutic 
effectiveness with agents targeting pathological processes 
in LBD.
We have previously shown that altered endoplasmic retic-
ulum (ER) stress and unfolded protein response is present in 
LBD and in GBA mutation carriers [50], and suggest that the 
altered ceramide levels in EV may originate in the ER–Golgi 
system. Retention of misfolded mutant forms of GBA within 
the ER may underlie the higher risk and earlier age at onset 
of LBD, as GBA mutation contributes to an earlier overload 
of ER compared to typical late onset cases [24, 74, 75]. As 
the de novo synthesis of ceramide occurs in the ER [37], cer-
amide synthesis may be altered as a result of the loss of pro-
tein homeostasis within the ER. It has recently been shown 
that chemically induced ER stress in human retinal pigment 
epithelium cells leads to increased ceramide levels, along 
with increased levels of pro-apoptotic factors [3]. Alpha-
synuclein accumulation can cause ER stress and inhibition 
of ER–Golgi trafficking, leading to cytotoxicity [20]. As 
ceramides are key regulators of programmed cell death [62], 
upregulation of ceramide may be part of a process associated 
with cell stress. The loss of lipid homeostasis in LBD and 
GBA mutation carriers shown here and elsewhere [18] may 
also indicate a general loss of lysosomal homeostasis and 
lysosomal degradative capacity. It has been suggested that 
GBA deficiency might lead to changes in the composition 
of lysosomal membranes, affecting alpha-synuclein degra-
dation and other autophagic processes [80]. A pathological 
loop between alpha-synuclein accumulation, reduction of 
GBA activity through alpha-synuclein-driven blockage of 
lysosomal delivery, and generation of abnormal lipid profiles 
that might further enhance alpha-synuclein misfolding, may 
underlie the modifying effect of GBA in increasing suscep-
tibility to LBD [24, 38, 59, 95].
Sphingolipids are important molecules in cellular signal 
transduction. Ceramide is the backbone of complex gly-
cosphingolipids, and ceramide signalling can culminate in 
apoptosis, autophagy and cell cycle arrest. Cellular ceramide 
levels need to be balanced to regulate cell death and prolif-
eration, a feature of a key tumour suppressor [62]. Accu-
mulating evidence links ceramide with LBD (for review 
see [70]). A genetic association between PD and ASAH1, 
the gene coding for the acid ceramidase enzyme involved in 
degradation of ceramide in lysosomes has been identified 
[73]. Research has also shown that disruption of retromer 
function either by ablation of Parkinsonism related PLA2G6 
and VPS35, or by overexpression of alpha-synuclein, leads 
to ceramide accumulation, lysosomal and mitochondrial 
stress, and neurodegeneration [54]. As ceramide reduction 
rescues the neurodegenerative phenotype, there is compel-
ling evidence that ceramide accumulation may cause nerve 
cell loss [54]. Interestingly, the loss of LRRK2 (PARK8) has 
also been associated with retromer dysfunction and ceramide 
accumulation, indicating multiple genetic pathways asso-
ciated with LBD involve ceramides [26, 55]. Our current 
study underscores the importance of the ceramide/sphin-
golipid pathway in sporadic LBD. The functional effect of 
specific ceramides may be either “physical” and involve their 
membrane stabilising properties and/or bioactive and related 
to the potent signalling functions of ceramides. Increased 
levels of cellular ceramides associate with decreased mem-
brane fluidity and as a result, abnormal vesicular transport. 
Increased ceramides also constitute pro-apoptotic and pro-
inflammatory signals, and affect mitochondrial homeosta-
sis, common features of alpha-synucleinopathies [70]. The 
elevation of ceramides in LBD EV might be a mechanism 
of cells to dispose of excess lipids, similar to that observed 
in sphingolipidoses [78].
Our observations show that brain alpha-synuclein pathol-
ogy is similar in LBD GBA mutation carriers and non-car-
riers. We also demonstrate that alpha-synuclein is present 
in EV in LBD and control samples, but with no significant 
changes in alpha-synuclein levels between patients and con-
trols using ELISA and western blot analyses. It is therefore 
possible that an altered structure of alpha-synuclein in EV, 
such as fibrils, truncation, or strong alpha-synuclein–EV 
membrane binding detected by our NMR analysis, may be 
ways in which EV act as seeds for alpha-synuclein aggre-
gation. The high abundance of heat shock 70 kDa protein 
(HSPA4) in DLB EV determined by mass spectrometry 
analysis (see Online Resource Table 4) might be an indica-
tor of misfolded alpha-synuclein since HSPA4 can directly 
bind to alpha-synuclein fibrils and cause fibril disassembly 
[30]. Our NMR experiments indicate an initial weak bind-
ing of the C-terminus of alpha-synuclein to EV and this 
binding has been reported to be modulated by the presence 
of  Ca2+ ions and by the presence of three distinct protein 
regions within alpha-synuclein [27, 52]. Using DLB EV to 
aggregate alpha-synuclein correlates with previous observa-
tions of alpha-synuclein membrane binding and is sugges-
tive of a disordered C-terminus with low membrane affinity 
and strong membrane binding via the N-terminus of alpha-
synuclein [27, 57].
The observation of the distinctive cleavage patterns in 
the different PDD EV by NMR correlated with the pres-
ence of proteases, such as caspases, in the EV proteomes, 
that have been previously implicated in facilitating alpha-
synuclein aggregation in vitro [91], and likely indicating 
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the contribution of cleaved alpha-synuclein species to the 
fibrillisation of these samples. In contrast, the upregulation 
of maintenance proteins in DLB derived EV, such as pro-
teasomal machineries might indicate impaired proteolytic 
clearance possibly due to post-translational modifications of 
cellular alpha-synuclein impairing this process [16]. It has 
been shown that the impairment of the cellular protein qual-
ity control machinery leads to the accumulation of alpha-
synuclein at the mitochondrial membranes [16], which may 
then trigger the aggregation process by stimulating primary 
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nucleation [28]. Our observations of the upregulation of 
several mitochondrial proteases such as calpains (reviewed 
in [72]) in DLB EV may suggest impaired mitochondrial 
function, further supported by the upregulation of PARK7/
DJ1 which is linked to oxidative stress, mitochondrial dys-
function and prevention of alpha-synuclein aggregation 
[94]. Impaired mitochondrial function also shows links 
with the recent characterisation of Lewy bodies as contain-
ing aggregated proteins and damaged organelles including 
mitochondria [51, 56, 81]. These observations need careful 
consideration however, as they were derived from a limited 
dataset.
Our results with EV using protein aggregation assay also 
strongly implicate alpha-synuclein fibrillisation upon EV 
membrane binding. Intact EV membranes are essential for 
the process of EV-mediated aggregation of alpha-synuclein 
[89]. It is unclear if this effect is exerted by membrane 
lipids, membrane curvature, membrane-associated pro-
teins, or other factors such as those identified in this study. 
Nonetheless, there is accumulating evidence that vesicles 
are powerful inducers of alpha-synuclein fibrillisation [28, 
29, 34, 85]. The altered lipid composition of LBD EV iden-
tified in this study may contribute to the abnormal alpha-
synuclein misfolding and this interaction may be a major 
driver of the alpha-synuclein aggregation process. As cera-
mides are specifically enriched in LBD vesicles it may be 
that the abnormally high levels of ceramides are involved 
in the protein aggregation process in a similar manner to 
glucosylceramide [95] or GM1 and GM3 gangliosides, all 
substrates in the glycosphingolipid metabolism pathway. 
GM1 and GM3 gangliosides have been shown to acceler-
ate alpha-synuclein toxic conversion in exosomes, and the 
role of these gangliosides in LBD warrants further vali-
dation [34]. Since we also demonstrate the presence of a 
wide range of neurodegeneration-linked proteins contained 
within LBD EV and a significant enrichment of pro-inflam-
matory protein signatures (see below), we suggest that EV 
play a role as signalosomes and transmit stress signals and 
disease features to other cells. EV are taken up by cells and 
patient-derived EV are capable of inducing alpha-synuclein 
aggregation in host cells [66, 85]. Our current study adds to 
these findings by identifying cell signalling proteins, lipid 
alteration and potential exchange, and cell stress stimula-
tory properties to the portfolio of processes that could be 
affected by neural EV.
Gene Ontology Biological Process term enrichment 
analysis of differentially expressed proteins identified in 
the LBD and control EV revealed apparent downregulation 
of GABAergic synaptic activity and upregulation of pro-
inflammatory glycolytic metabolism in DLB EV. We have 
previously described altered GABAergic neuronal function 
in LBD visual cortex, and the current study indicates that 
functional changes in GABAergic neurons may be an inher-
ent feature of LBD [48]. The accompanying pro-inflamma-
tory signature of LBD EV may also reflect the activation of 
immune cells and the increased amounts of EV from this 
source in the total pool of circulating EV. Activated micro-
glia and astrocytes switch their metabolism to glycolysis to 
fuel inflammation [83]. This observation correlates with 
elevated gene expression of microglial and astrocytic inflam-
matory markers in widespread cortical areas in LBD (unpub-
lished observations) and suggest that EV may be mediators 
of neuroinflammation.
In summary, our findings indicate that abnormal 
ceramide levels are a feature of LBD independent of 
GBA mutation status, and these ceramide alterations are 
prominent within EV. These ceramide changes may be 
related to the ER stress caused by GBA protein misfold-
ing and general loss of endolysosomal homeostasis and 
lysosomal degradation capacity, and consequently cause 
abnormal pathogenic alpha-synuclein to be associated 
with EV. This elevation of ceramide in CSF EV and the 
highly alpha-synuclein aggregation-promoting properties 
of EV may provide a diagnostic and therapeutic marker 
of LBD.
Fig. 5  Proteomics of LBD post-mortem frontal cortex derived extra-
cellular vesicles. a Enrichment of exosomal proteins in the frontal 
cortex derived EV samples. Proteins were annotated by Gene Ontol-
ogy Cellular Component (GOCC) and the term enrichment was 
done using the DAVID web-based tool. Results are presented as a 
correlation of dataset fraction annotated by the given term and Ben-
jamini–Hochberg corrected p-value of the enrichment test. b Label-
free quantitation (LFQ) intensities of alpha- (SNCA), beta- (SNCB), 
gamma- (SNCG) synucleins and Tau protein in EV samples isolated 
from control and DLB patients showed the presence of proteins but 
no major changes in levels. c Hierarchical clustering of differentially 
expressed proteins in EV isolated from control and DLB patients. 
Significance was determined by t test. The colouring scheme cor-
responds to Z-score-transformed protein intensity; proteins absent 
in the given sample are represented by grey colour. Two clusters of 
proteins with similar distribution across sample types are emphasised. 
Gene Ontology Biological Process (GOBP) terms enrichment for 
each cluster was done using DAVID web-based tool and p-values for 
associated GO terms are shown in graphs of the corresponding clus-
ter colour. Plus (+) and minus (−) denotes the presence or absence 
of GBA heterozygous mutation. d LFQ intensities of selected proteins 
annotated by cluster-specific GOBP terms. Colour of gene name cor-




Fig. 6  Immuno-electron micros-
copy of extracellular vesicles 
associated alpha-synuclein. a, b 
Alpha-synuclein was detected 
as membrane labelling and c, 
d within the vesicle interior 
(post-permeabilisation label-
ling) in CSF-derived EV from 
control (a, c) and LBD samples 
(b, d). e Positive CD63 label-
ling indicates the presence of 




Fig. 7  Characterisation of interactions between post-mortem frontal 
cortex derived extracellular vesicles and alpha-synuclein by NMR. a 
Scheme of the experimental set-up to investigate the effect of aggre-
gation on the interaction between alpha-synuclein and patient-derived 
EV. b–f  [15N,1H]-NMR spectra of 50  µM [U–15N,13C]-alpha-synu-
clein in PBS (black) and following the addition of EV of different 
origins as indicated after aggregation for 48 h at 30 °C. g, h Residue-
resolved backbone amide NMR signal attenuation (g) and chemical 
shift changes (h) of alpha-synuclein upon addition of control GBA 
WT EV (red), PDD GBA WT EV (dark orange), PDD GBA MT EV 
(light orange), and DLB GBA WT EV (yellow: data multiplied by a 
factor of 10). As a further control, no EV were added (purple). The 
grey outline overlaying the PDD EV samples intensity data is alpha-
synuclein in the presence of 15 mg/ml LUVs, representing the signal 
attenuation upon vesicle binding [16]. i Estimation of the distribu-
tions of monomeric alpha-synuclein, its vesicle bound and aggregated 
form for the tested samples
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Fig. 8  LBD patient-derived EV induce aggregation of wild-type 
alpha-synuclein in RTQuIC assay. a Exponential curves indicate the 
generation of alpha-synuclein aggregates upon addition of LBD-
derived EV and EV derived from control individuals with incidental 
Lewy body pathology without LBD symptoms. Flat lines signify the 
lack of aggregate formation in controls (individuals with no pathol-
ogy present and unseeded assay control). b Representative TEM 
images of post-RTQuIC samples from DLB (×50,000 magnifica-
tion), PDD (×15,000 magnification), and PD (×15,000 magnification) 
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